Oxurion to Participate in Needham Virtual Healthcare Conference
March 28 2022 - 2:00AM
Oxurion to Participate in Needham Virtual Healthcare Conference
Leuven, BELGIUM, Boston, MA, US - MARCH
28, 2022 – 8.00 AM CET
– Oxurion NV
(Euronext Brussels: OXUR) (the
"Company" or "Oxurion"), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, announces today that Tom Graney, Chief Executive
Officer, will present at the 21st Annual Needham Virtual Healthcare
Conference on Monday, April 11, 2022 at 9:30 AM ET.
A live webcast and 90-day archive will be available in the
“Investors” section of the Company’s website.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (wet AMD) and macular edema
following retinal vein occlusion (ME-RVO). Oxurion is aiming to
build a leading global franchise in the treatment of retinal
vascular disorders based on the successful development of its two
novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of DME patients showing suboptimal response to anti-VEGF
therapy. THR-687 is a highly selective pan-RGD integrin antagonist
that is being developed as a potential first line therapy for DME
patients as well as wet AMD and potentially ME-RVO. Oxurion is
headquartered in Leuven, Belgium, with corporate operations in
Boston, MA. More information is available at www.oxurion.com.
For more information, please contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël
DillenChief Business OfficerTel: +32 479 783
583michael.dillen@oxurion.com |
EUMEDiSTRAVA ConsultingDavid
Dible/ Sylvie Berrebi/Frazer HallTel: +44 203 928
6900oxurion@medistrava.com
USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2023 to Apr 2024